RE: This one has to get betterbaba,
i think most of the disgruntled posters, myself included, likely share your view to some degree, otherwise they wouldn't still be here and so pissed off.
but when you hear, after the fact, that the largest shareholder has bailed before the "soon" to be released "positive" trial results, and of the departure of schnarr, several months after he actually left, all without ANY official public comment by the company, it is yet another indication that if something is wrong, onc management will be the last to provide any comment.
the market, despite the apparent favorable change in the FDA's approval process for cancer treatments like erbitux, isn't reflecting the "positiveness" of this change on reolysin's prospects - why? you can be sure it isn't because the market isn't aware of the approval of erbitux and the apparent change in FDA parameters.
the bottom line is that either the market is wrong about the potential of onc/reolysin or that all the positive spin & hype posted here about onc is baseless.
BT & MC have done little to advance reolysin & onc, imo.
i think they have gone a long way to proving they are rank amateurs when it comes to moving reolysin to commercialization - we are approaching the second anniversary of a small 15 patient ph II prostate trial, where one of the advantages promoted for participation in the trial was a shorter wait for surgery.
in their 2001 annual report, they publicly stated their goal was to commence a ph II systemic trial in 2002 - it is now 2004 and they still have the same goal!
these guys are running this company like it is their own private fiefdom - they are well-compensated, but fail to give account to their shareholders as to the status of their trials and the reasons for the delays. they get away with it, because too many of their shareholders for some reason are willing to blindly trust them, hoping against hope, that like squirrels suffering the same affliction, they will stumble across a nugget.
little to no news + no accountability = much greater risk of failure
the best and honourable thing these guys could and should do for the advancement of reolysin and onc share value, imo, is resign, and put up the company assets for sale to the highest bidder where they relinquish any right to individual royalties in return for shares of the acquiring company.
i know that may sound drastic, but their lack of trial progress over the last 2 years has been just as, if not more, drastic.
if these guys aren't going to provide regular updates and explanations for delays to shareholders, its time for shareholders to "update" management, to remind them of who is accountable to who.
ps to preempt any lame and pathetic defense of onc management, holding hundreds of thousands of unexercised options doesn't make them shareholders, so don't even bring that up.